We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · February 03, 2021

Measurable Residual Disease Affects Allo-HCT in Ph+ Acute Lymphoblastic Leukemia

Blood Advances


Additional Info

Disclosure statements are available on the authors' profiles:

Blood Advances
Measurable Residual Disease Affects Allogeneic Hematopoietic Cell Transplantation in Ph+ ALL During Both CR1 and CR2
Blood Adv 2021 Jan 26;5(2)584-592, S Nishiwaki, Y Akahoshi, S Mizuta, A Shinohara, S Hirabayashi, Y Noguchi, T Fukuda, N Uchida, M Tanaka, M Onizuka, Y Ozawa, S Ota, S Shiratori, Y Onishi, Y Kanda, M Sawa, J Tanaka, Y Atsuta, S Kako

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading